Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBXA2R | P21731 | 8/20 | 0.38 |
| ▸ | PPARA | Q07869 | 7/20 | 0.35 |
| ▸ | PPARG | P37231 | 7/20 | 0.35 |
| ▸ | TBXAS1 | P24557 | 4/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10273021 | 0.96 | TBXA2R (0.40) | TBXA2RPPARGTBXAS1 | |
| SCHEMBL882894 | 0.89 | HSP90AA1 (0.38) | PPARAPPARGLMNAL3MBTL1 | |
| SCHEMBL10273807 | 0.86 | HSP90AA1 (0.37) | PPARAPPARGLMNAL3MBTL1 | |
| SCHEMBL10273210 | 0.83 | TBXA2R (0.44) | TBXA2RTBXAS1LMNAHTTL3MBTL1 | |
| SCHEMBL882650 | 0.83 | HSP90AA1 (0.34) | PPARAPPARG | |
| SCHEMBL882865 | 0.82 | HSP90AA1 (0.38) | PPARAPPARGLMNAL3MBTL1 | |
| SCHEMBL10273698 | 0.82 | HSP90AA1 (0.38) | PPARAPPARGLMNAL3MBTL1 | |
| SCHEMBL10272879 | 0.82 | HSP90AA1 (0.33) | PPARG | |
| SCHEMBL882652 | 0.82 | HSP90AA1 (0.33) | PPARG | |
| SCHEMBL882995 | 0.81 | P2RX7 (0.40) | PPARAPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| US-20140309244-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2014-10-16 | — | — | US | disclosed |
| WO-2012038521-A1 | NOVEL MICROBIOCIDES | SYNGENTA PARTICIPATIONS AG (CH) | 2012-03-29 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140309244-A1 | NOVEL MICROBIOCIDES | MSR1, C3AR1, CD209 | TBXA2R 1428/4885PPARA 3301/4885PPARG 3152/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.